Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Kronos Bio Inc
KRONKronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California. Address: 1300 So. El Camino Real, San Mateo, CA, United States, 94402
Analytics
Preço Alvo de Wall Street
2.25 USDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave KRON
Análise de Dividendos KRON
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos KRON
Avaliação de ações KRON
Relatório KRON
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |